Related Experiment Video

Updated: Nov 3, 2025

Comprehensive Analysis of Procoagulant Platelets Exhibiting Features of Necrosis, Apoptosis and Platelet Activation
04:37

Comprehensive Analysis of Procoagulant Platelets Exhibiting Features of Necrosis, Apoptosis and Platelet Activation

Published on: May 23, 2025

802

Platelet-driven coagulopathy in COVID-19 patients: in comparison to seasonal influenza cases

Jianguo Zhang1,2, Xing Huang3, Daoyin Ding4

  • 1Jiangsu Province Key Laboratory of Medical Science and Laboratory Medicine, School of Medicine, Jiangsu University, Zhenjiang, 212013, Jiangsu, China.

Experimental Hematology & Oncology
|June 1, 2021
PubMed

Insights

COVID-19 patients exhibit distinct blood coagulopathy compared to influenza, with severe cases showing higher bleeding risk when treated with anticoagulants. Understanding these differences aids in developing targeted therapies for SARS-CoV-2 infections.

Area of Science:

  • Hematology
  • Infectious Diseases
  • Pathophysiology

Background:

  • The COVID-19 pandemic highlighted significant coagulopathy in patients.
  • Comparative analysis with influenza infections was needed to understand SARS-CoV-2 specific mechanisms.

Purpose of the Study:

  • To analyze and compare blood coagulopathy in severe and non-severe COVID-19 patients versus influenza patients.
  • To identify differences in coagulation profiles and their association with disease severity and treatment outcomes.

Main Methods:

  • A cohort study involving 461 COVID-19 and 409 influenza patients.
  • Detailed analysis of demographic data, medical history, and hematological profiles, including coagulation parameters.
  • Comparison of coagulation markers before and after treatment between the two groups.

Main Results:

  • COVID-19 patients showed leukocytosis, neutrophilia, lymphocytopenia, and thrombocytopenia, linked to severity.
  • Prolonged PT and aPTT, increased INR, shortened thrombin time, and decreased fibrinogen were observed in COVID-19 patients.
  • Platelet hyperreactivity and refractory coagulopathy were more pronounced in COVID-19, with higher bleeding incidence in severe cases on anticoagulants.

Conclusions:

  • Coagulation differences between COVID-19 and influenza offer insights into SARS-CoV-2 pathogenesis.
  • Understanding these mechanisms can guide therapeutic improvements for COVID-19-related coagulopathy.
Abstract

Keywords:
COVID-19Coagulation disorderInfluenzaIntensive care unitSARS-CoV-2

More Related Videos

Microfluidics in Assessing Platelet Function06:47

Microfluidics in Assessing Platelet Function

Published on: November 8, 2024

1.2K
A Mouse Model for the Transition of Streptococcus pneumoniae from Colonizer to Pathogen upon Viral Co-Infection Recapitulates Age-Exacerbated Illness12:21

A Mouse Model for the Transition of Streptococcus pneumoniae from Colonizer to Pathogen upon Viral Co-Infection Recapitulates Age-Exacerbated Illness

Published on: September 28, 2022

2.8K

Related Concept Videos

Formation of the Platelet Plug01:22

Formation of the Platelet Plug

The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
7.9K
Structure and Function of Platelets01:18

Structure and Function of Platelets

The cell fragments known as platelets are disc-shaped, with an average diameter of about 3 μm and a thickness of roughly 1 μm. They play a crucial role in the body's vascular clotting system, which also involves plasma proteins, blood cells, and blood vessel tissues.
Platelets are continually replenished, circulating in the bloodstream for 9-12 days before being removed by phagocytes, primarily in the spleen. A microliter of circulating blood contains between 150,000 and 450,000...
2.3K
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
1.2K
Coagulation01:09

Coagulation

The coagulation phase is a critical part of the body's process to prevent blood loss following injury to blood vessels. It involves chemical reactions that form a clot to seal the injured area. The clotting process begins shortly after injury, within 15-20 seconds for severe damage and 1-2 minutes for minor injuries.
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...
8.6K
Coagulation01:06

Coagulation

Colloidal solids are solid particles suspended in solution. They are usually negatively charged, attracting a compact primary layer of positively charged ions, which attract more counterions to form an electrical double layer. Electrostatic repulsion between the charged double layers prevents the particles from colliding, stabilizing the colloids. These solids are often undesirable because they can contain toxins that are difficult to remove. Coagulation is a technique that helps aggregate and...
545